Neuroscience Project Rankings is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms.
This page ranks major neuroscience research projects by impact and data availability for neurodegenerative disease research. Rankings are based on multiple factors including data quality, accessibility, disease relevance, completeness, and community adoption.
Projects are evaluated on multiple dimensions to provide meaningful guidance for researchers:
| Rank | Project | Disease Focus | Data Types | Impact Score |
|---|---|---|---|---|
| 1 | SEA-AD | Alzheimer's | Single-cell, spatial | 10 |
| 2 | ADNI | Alzheimer's | MRI, PET, CSF | 10 |
| 3 | Allen Brain Cell Atlas | General | Single-cell, transcriptomics | 9 |
| 4 | PPMI | Parkinson's | Clinical, imaging, biosamples | 9 |
| 5 | Human Connectome Project | General | Diffusion, functional MRI | 8 |
| Rank | Project | Disease Focus | Data Types | Impact Score |
|---|---|---|---|---|
| 6 | BICCN | General | Cell census, multimodal | 8 |
| 7 | BrainSpan | Development | Transcriptomics | 8 |
| 8 | NEURON | Alzheimer's, Parkinson's, ALS | Clinical, genomics, imaging | 7 |
| 9 | Allen Brain Observatory | General | Calcium imaging, electrophysiology | 7 |
| 10 | Allen Mouse Brain Atlas | General | Gene expression, anatomy | 7 |
| 11 | Human Brain Atlas | General | Transcriptomics, anatomy | 7 |
| 12 | EU JPND | Multi-disease | Cross-cohort data, biobank | 7 |
The SEA-AD project represents a landmark in Alzheimer's disease research, applying single-nucleus RNA sequencing to well-characterized human brain tissue from donors across the disease spectrum[1]. The project integrates spatial transcriptomics to map gene expression within tissue architecture, revealing cell-type-specific vulnerability patterns. Researchers can explore cell type composition, differential expression, and spatial organization in the context of Alzheimer's pathology.
Best for: Understanding cell-type specific AD mechanisms, identifying vulnerable neuron populations, and generating disease hypotheses
ADNI has transformed Alzheimer's clinical research by establishing standardized protocols for neuroimaging and biomarker assessment[2]. With over 15 years of longitudinal data from thousands of participants, ADNI enables studies of disease progression, biomarker validation, and clinical trial design. Data includes structural MRI, PET imaging, CSF and blood biomarkers, and comprehensive clinical assessments.
Best for: Biomarker validation, disease progression studies, and clinical trial endpoint development
This comprehensive cell type atlas combines single-cell transcriptomics with other modalities to classify cell types across brain regions and species[3]. The atlas provides standardized cell type nomenclature, gene expression markers, and integrated data exploration tools.
Best for: Cell type classification, marker gene discovery, and cross-species comparisons
PPMI systematically collects clinical, imaging, genetic, and biosample data from Parkinson's disease patients and healthy controls[4]. The study focuses on identifying progression markers that can inform clinical trial design and understanding of disease mechanisms.
Best for: PD biomarker discovery, progression marker identification, and genetic studies
EU JPND is Europe's largest research collaboration on neurodegenerative diseases, bringing together over 30 countries to coordinate research efforts across Alzheimer's, Parkinson's, ALS, frontotemporal dementia, and other NDs[5]. The programme funds transnational research consortia, establishes shared data platforms, and promotes harmonization of methodologies across Europe. Key initiatives include cohort studies, biomarker validation projects, and clinical trial optimization studies.
Best for: Cross-cohort analyses, European patient populations, and harmonized methodology
NEURON coordinates multinational research projects on neurodegenerative diseases funded through EU framework programmes[6]. The network focuses on translational research, biomarker development, and therapeutic target identification. Projects under NEURON cover Alzheimer's disease, Parkinson's disease, ALS, and rare neurodegenerative conditions, with emphasis on data sharing and reproducibility.
Best for: Translational research, biomarker development, and therapeutic target discovery
Start with SEA-AD for molecular mechanisms and ADNI for clinical translation. These projects provide complementary views of disease from cellular to systems level.
PPMI serves as the primary resource for biomarker discovery and disease progression understanding. Combine with relevant animal model data for mechanism studies.
The Allen Brain Cell Atlas and BICCN provide foundational cell type classification data essential for understanding cellular diversity in any brain region.
The Human Connectome Project provides essential reference data for understanding typical brain connectivity, which serves as a baseline for understanding disease-related changes.
The following areas need additional content or pages:
Mathys, H. et al. (2023). Single-cell atlas reveals correlates of Alzheimer's disease pathology. Nature. 2023. ↩︎
Weiner, M.W. et al. (2013). The Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia. 2013. ↩︎
Zeng, H. & Sanes, J.R. (2017). Neuronal cell-type classification. Nature Neuroscience. 2017. ↩︎
Marek, K. et al. (2011). The Parkinson Progression Marker Initiative. Progress in Neurobiology. 2011. ↩︎
EU JPND. Joint Programme - Neurodegenerative Disease Research. 2026. ↩︎
NEURON. Network of European Research Projects. 2026. ↩︎